The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1250 articles
The FDA has approved Novo Nordisk's Wegovy as an oral medication for weight loss. This provides an alternative to injections for adults with obesity or weight-related health issues. The company anticipates a US launch in January.
GLP-1 medications, while effective for weight loss, can have various side effects. Understanding these potential impacts is crucial for informed decision-making and patient care. These medications affect different parts of the body, leading to diverse reactions based on individual physiology.
Karl Stefanovic recently displayed his weight loss while enjoying a beach day in Noosa with family. The TV personality appeared happy and healthy as he strolled along the shoreline. This comes after a previous 'dad bod' moment spurred him to get in shape.
A leading GP has identified six holiday foods that individuals using weight-loss injections should avoid during Christmas. These foods can trigger unpleasant side effects due to the medication's impact on digestion. Adjusting your diet can help mitigate these risks.
GLP-1 drugs are effective for rapid weight loss, but can lead to skin laxity and premature aging. Vol.U.Lift cream, created by a plastic surgeon, is designed to combat these effects, offering a topical solution to keep skin firm and smooth.
Trinny Woodall shares her Saturday routine, emphasizing rest and indulgence. From morning supplements and walks to evening skincare and family time, discover how she balances self-care and relaxation.
ShantaQuilette Carter-Williams shares her experience with GLP-1 medication after a health ultimatum. Discover how it transformed her life, health habits, and perspective on self-care.
The ongoing discussion regarding insurer coverage for GLP-1 medications such as Ozempic and Wegovy has reignited a familiar debate concerning the origins of illness. Some argue these weight-loss drugs are shortcuts, while others emphasize the impact of socioeconomic factors on body weight.
A recent study has uncovered a potential connection between glucagon-like peptide-1 (GLP-1) receptor agonists and chronic cough in individuals managing type 2 diabetes. The research suggests that those using GLP-1 drugs were more prone to developing a persistent cough compared to those on alternative second-line treatments.
